Company Filing History:
Years Active: 1998-2000
Title: The Innovative Mind of James A. Trofatter
Introduction
James A. Trofatter, based in Charlestown, MA, is a notable inventor whose contributions to the field of biomedical science have been recognized through his two patents. His work primarily focuses on understanding and utilizing the tumor suppressor protein, merlin, which plays a crucial role in cancer research and treatment.
Latest Patents
Trofatter's latest patents revolve around the novel tumor suppressor protein, merlin. The first patent details the identification of this protein, providing DNA sequences that encode merlin as well as recombinant vectors and hosts capable of expressing it. This work is integral for the development of methods for diagnosing and treating merlin-associated tumors, including the disease neurofibromatosis 2 (NF2). His second patent reiterates these groundbreaking findings, further solidifying his contributions to the understanding of merlin as a tumor suppressor gene.
Career Highlights
Currently, James A. Trofatter is associated with The General Hospital Corporation, where he engages in pioneering research and development within the medical field. His extensive work has not only enriched scientific knowledge but has also paved the way for potential clinical applications that could improve patient outcomes in cancer treatment.
Collaborations
Throughout his career, Trofatter has collaborated with esteemed coworkers such as Mia M. MacCollin and James F. Gusella. These partnerships have enabled the fusion of innovative ideas and methodologies, leading to advancements in understanding complex genetic conditions.
Conclusion
James A. Trofatter stands out as an influential inventor whose work on the tumor suppressor protein merlin exemplifies the intersection of innovation and medicine. His patents are not only a testament to his ingenuity but also hold the promise of significant advancements in the diagnosis and treatment of tumors. As research in this area progresses, Trofatter’s contributions will likely continue to have a lasting impact on the field of biomedical science.